antibody or an antigen-binding fragment thereof. In certain embodiments, the antigen-binding fragment of the antibody is an Fab, Fab', $F(ab')_2$, Fv or single chain Fv (scFv).

The presently disclosed subject matter also provides a composition comprising the antibody or antigen-binding fragment thereof disclosed herein, and a pharmaceutically acceptable carrier.

In addition, the presently disclosed subject matter provides an immunoconjugate comprising the antibody or antigen-binding fragment thereof disclosed herein, linked to a therapeutic agent. In certain embodiments, the therapeutic agent is a drug, cytotoxin, or a radioactive isotope. The presently disclosed subject matter also provides a composition comprising such immunoconjugate and a pharmaceutically acceptable carrier.

Furthermore, the presently disclosed subject matter provides a bispecific molecule comprising the antibody or antigen-binding fragment thereof disclosed herein, linked to a second functional moiety. In certain embodiments, the second functional moiety has a different binding specificity than the antibody or antigen binding fragment thereof. In certain embodiments, the second functional moiety has a binding specificity for an immune cell. In certain embodiments, the second functional moiety has a binding specificity for CD3.

The presently disclosed subject matter also provides a composition comprising such bispecific molecule and a pharmaceutically acceptable carrier.

In addition, the presently disclosed subject matter provides an isolated nucleic acid that encodes the antibody or antigen-binding fragment thereof disclosed herein, an expression vector comprising such nucleic acid molecule, and a host cell comprising gsuch expression vector.

Furthermore, the presently disclosed subject matter provides a method for detecting GPRC5D in a whole cell or tissue. In certain embodiments, the method comprises: contacting a cell or tissue with the antibody or antigen-binding fragment thereof disclosed herein, wherein said antibody or antigen-binding fragment thereof comprises a detectable label; and determining the amount of the labeled antibody or antigen-binding fragment thereof bound to said cell or tissue by measuring the amount of detectable label associated with said cell or tissue, wherein the amount of bound antibody or antigen-binding fragment thereof indicates the amount of GPRC5D in said cell or tissue.

Furthermore, the presently disclosed subject matter provides use of an effective amount of the antibody or antigen-binding fragment thereof as described herein, in the manufacture of medicament for treating a tumor in a subject.

51. A composition comprising the bispecific molecule of claim 47, 48, 49 or 50 and a pharmaceutically acceptable carrier.

52. An isolated nucleic acid that encodes an antibody or antigen-binding fragment thereof of any one of claims 1-42.

53. An expression vector comprising the nucleic acid molecule of claim 52.

54. A host cell comprising the expression vector of claim 53.

55. A method for detecting GPRC5D in a whole cell or tissue, comprising:

contacting a cell or tissue with the antibody or antigen-binding fragment thereof of any one of claims 1-42, wherein said antibody or antigen-binding fragment thereof comprises a detectable label; and

determining the amount of the labeled antibody or antigen-binding fragment thereof bound to said cell or tissue by measuring the amount of detectable label associated with said cell or tissue, wherein the amount of bound antibody or antigen-binding fragment thereof indicates the amount of GPRC5D in said cell or tissue.

56. Use of an effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-42, in the manufacture of medicament for treating a tumor in a subject.

57. The use of claim 56, wherein the method reduces the number of the tumor cells.

58. The use of claim 56, wherein the method reduces the tumor size.

59. The use of claim 56, wherein the method eradicates the tumor in the subject.

60. The use of any one of claims 56-59, wherein the tumor is multiple myeloma or Waldenstrom's Macroglobulinemia.

61. The use of claim 60, wherein the tumor is multiple myeloma.

62. The use of any one of claims 56-61, wherein the subject is a human.

63. A kit for treating a tumor, comprising the antibody or antigen-binding fragment thereof of any one of claims 1-42.

64. The kit of claim 63, wherein the kit further comprises written instructions for using the antibody or antigen-binding fragment thereof for treating a subject having a tumor.

65. The kit of claim 63 or 64, wherein the tumor is multiple myeloma or Waldenstrom's Macroglobulinemia.

66. The kit of claim 63, 64 or 65, wherein the tumor is multiple myeloma.